108 results
8-K
EX-1.1
ANNX
Annexon Inc
7 Jun 24
Annexon Announces Pricing of $125 Million Underwritten Public Offering
4:42pm
” (within the meaning of Sections 304 and 305 of ERISA) (v) the fair market value of the assets of each Plan exceeds the present value of all benefits … benefits received by the Company, on the one hand, and the Underwriters on the other, from the offering of the Offered Securities or (ii) if the allocation
8-K
EX-99.1
ANNX
Annexon Inc
7 Jun 24
Annexon Announces Pricing of $125 Million Underwritten Public Offering
4:42pm
therapeutic candidates are designed to provide meaningful benefits across multiple autoimmune, neurodegenerative and ophthalmic diseases. With proof-of concept
424B5
ANNX
Annexon Inc
6 Jun 24
Prospectus supplement for primary offering
9:57pm
regarding their entitlement to benefits under any applicable income tax treaty.
Exercise of pre-funded warrants
A non-U.S. holder generally … of us to first negotiate with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate
FWP
ANNX
Annexon Inc
5 Jun 24
Free writing prospectus
7:56pm
for certain items. Non-U.S. holders should consult their tax advisors regarding their entitlement to benefits under any applicable income tax treaty
424B5
ANNX
Annexon Inc
4 Jun 24
Prospectus supplement for primary offering
5:21pm
, including certifying the Non-U.S. Holder’s entitlement to benefits under that treaty and, in certain circumstances, providing such Non-U.S. Holder’s U.S … their entitlement to benefits under any applicable income tax treaty.
We and other withholding agents are not required to withhold tax on dividends paid
8-K
EX-99.1
fl4qh57qsb
4 Jun 24
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
7:05am
8-K
EX-99.1
t2df4ycpc0q99 3hm0
13 May 24
Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones
4:05pm
8-K
EX-99.1
65xhoy
7 May 24
Other Events
4:05pm
424B5
kkslxcu5
5 Apr 24
Prospectus supplement for primary offering
4:07pm
8-K
EX-99.1
pnpq ypmf
26 Mar 24
Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones
4:05pm